Overall, these studies indicate that p-tau, particularly p-tau 181, may serve as a more specific and reliable biomarker for AD compared to t-tau, offering improved accuracy in diagnosis and differentiation from other NDDs. This evidence concerns the gene MAPT and Alzheimer disease.